Research
Cancer Treatment with Actinomycin-D and Vincristine
A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer
Protocol Description
The purpose of this multi-center study is to gain a better understanding of what happens to the drugs Actinomycin-D (dactinomycin) and/or vincristine after they are administered to children for treatment of cancer. Both drugs have been used for more than 40 years, but doctors still don’t know why some children develop serious side effects, while others do not. Through blood and urine sampling, researchers will study how these drugs react and are processed by the body.
Eligibility Criteria
Boys and girls up to age 17 who are diagnosed with cancer and being treated with dactinomycin and/or vincristine will be eligible for consideration in the study.
Boys: Up to age 17
Girls: Up to age 17
Requirements
Urine and blood samples will be taken in conjunction with the child’s chemotherapy with dactinomycin and vincristine. Blood samples will be taken on the day of chemotherapy, once the next day and once 2 to 4 days later.
Frequency of visits: 4 consecutive days
Duration: 6 months of follow-up
Status: Open For Enrollment
Sources of Support
Children’s Oncology Group
National Cancer Institute
Additional Resources
Study Description at National Institutes of Health
Primary Investigator(s)
Regina Jakacki, MD
Contact Information
To get started, please contact:
Sharon DiBridge, CRA
412-692-7070
Angela Krol, Research RN, BSN
412-692-8047
